Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Immune-Onc Adds $25 Million to B Round for Novel Myeloid Checkpoint Inhibitors

publication date: Jan 6, 2023

Immune-Onc Therapeutics added $25 million from China investors to its Series B extension, bringing the total for the B round to $131 million. Immune-Onc is a Palo Alto, CA-Hangzhou company that is developing novel checkpoint inhibitors for cancer. In 2022, BayHelix, the global organization of China life science business leaders, awarded the R&D Achievement of the Year to the company for its first-in-class myeloid checkpoint inhibitors, which have started clinical trials. The $25 million extension was raised from existing investor Triwise Capital and new investor Proxima Ventures, among others. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital